Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam 0.12%



  Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam 0.12%

PR Newswire

ALLEGAN, Mich., Nov. 27, 2012

ALLEGAN, Mich., Nov. 27, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq:
PRGO;TASE) today announced that its partner, Cobrek Pharmaceuticals, Inc.,
received final approval from the U.S. Food and Drug Administration for its
Abbreviated New Drug Application (ANDA) for betamethasone valerate foam 0.12%,
the generic equivalent of Luxiq® Foam. Perrigo has manufactured the product
and is preparing to commence commercial shipments on January 15, 2013,
consistent with the date certain launch settlement. Cobrek was first to file,
making the product eligible for 180 days of marketing exclusivity.

(Logo:  http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

Betamethasone valerate foam 0.12% is indicated for the relief of
corticosteroid-responsive skin conditions of the scalp (scalp psoriasis).
Brand annual sales were approximately $40 million.

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This is our
sixth product approval using a foam dosage form, which requires specialized
development and manufacturing capabilities. It is an example of the excellent
partnership we have with Cobrek and we are committed to making quality
healthcare more affordable for our customers and drive value for our
shareholders."

From its beginnings as a packager of generic home remedies in 1887, Perrigo
Company, based in Allegan, Michigan, has grown to become a leading global
provider of quality, affordable healthcare products. The Company develops,
manufactures and distributes over-the-counter ("OTC") and generic prescription
("Rx") pharmaceuticals, nutritional products and active pharmaceutical
ingredients ("API") and is the world's largest manufacturer of OTC
pharmaceutical products for the store brand market. Perrigo's mission is to
offer uncompromised "quality, affordable healthcare products", and it does so
across a wide variety of product categories primarily in the United States,
United Kingdom, Mexico, Israel and Australia, as well as certain other markets
throughout the world, including Canada, China and Latin America. Visit Perrigo
on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements
within the meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and are subject to the safe harbor created thereby. These statements
relate to future events or the Company's future financial performance and
involve known and unknown risks, uncertainties and other factors that may
cause the actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those expressed or
implied by any forward-looking statements. In some cases, forward-looking
statements can be identified by terminology such as "may," "will," "could,"
"would," "should," "expect," "plan," "anticipate," "intend," "believe,"
"estimate," "predict," "potential" or other comparable terminology. The
Company has based these forward-looking statements on its current
expectations, assumptions, estimates and projections.  While the Company
believes these expectations, assumptions, estimates and projections are
reasonable, such forward-looking statements are only predictions and involve
known and unknown risks and uncertainties, many of which are beyond the
Company's control. These and other important factors, including those
discussed under "Risk Factors" in the Company's Form 10-K for the year ended
June 30, 2012, as well as the Company's subsequent filings with the Securities
and Exchange Commission, may cause actual results, performance or achievements
to differ materially from those expressed or implied by these forward-looking
statements. The forward-looking statements in this press release are made only
as of the date hereof, and unless otherwise required by applicable securities
laws, the Company disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise.

SOURCE Perrigo Company

Website: http://www.perrigo.com
Contact: Arthur J. Shannon, Vice President, Investor Relations and
Communication, +1-269-686-1709, ajshannon@perrigo.com, or Bradley Joseph,
Senior Manager, Investor Relations and Communication, +1-269-686-3373,
bradley.joseph@perrigo.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement